HeartSciences (NASDAQ:HSCS) Price Target Lowered to $9.00 at Ascendiant Capital Markets

HeartSciences (NASDAQ:HSCS) had its price target lowered by Ascendiant Capital Markets from $15.00 to $9.00 in a research note issued to investors on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Separately, Wall Street Zen raised HeartSciences to a “sell” rating in a research note on Saturday, July 26th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $10.50.

HeartSciences Stock Performance

HSCS opened at $3.70 on Wednesday. The firm has a market cap of $9.81 million, a P/E ratio of -0.45 and a beta of 2.57. HeartSciences has a 52-week low of $2.52 and a 52-week high of $6.47. The business’s fifty day moving average is $3.48 and its 200-day moving average is $3.53.

HeartSciences (NASDAQ:HSCS) last released its earnings results on Thursday, September 11th. The company reported ($1.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.41) by $0.83. On average, research analysts predict that HeartSciences will post -10.01 earnings per share for the current fiscal year.

Hedge Funds Weigh In On HeartSciences

An institutional investor recently bought a new position in HeartSciences stock. Astoria Strategic Wealth Inc. bought a new stake in HeartSciences Inc. (NASDAQ:HSCS) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 18,927 shares of the company’s stock, valued at approximately $53,000. Astoria Strategic Wealth Inc. owned about 1.75% of HeartSciences at the end of the most recent quarter. Hedge funds and other institutional investors own 17.24% of the company’s stock.

HeartSciences Company Profile

Heart Test Laboratories, Inc, a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals.